XAVANT TECHNOLOGY (PTY) LTD

Xavant Technology (Pty) Ltd specializes in three primary categories of medical devices: diagnostic peripheral nerve electrical stimulation systems, analgesic transcutaneous electrical nerve stimulation (TENS) systems for pain management, and medical networking interface units. These interface units enable communication between medical devices, ensuring seamless integration in clinical settings. The company’s portfolio includes standalone stimulation devices as well as modular solutions designed to work with existing equipment.

Xavant Technology (Pty) Ltd is based in the United States, which means its devices must comply with U.S. regulatory requirements, including those set by the FDA. The company’s products are designed to meet applicable domestic and international standards, ensuring they meet the necessary criteria for safety, performance, and regulatory listing—such as inclusion in the FDA’s Unique Device Identifier (UDI) database for certain devices.

Several of Xavant Technology’s devices are listed in the FDA’s Unique Device Identifier (UDI) database, which is a key registry for tracking medical devices in the U.S. market. Inclusion in this database helps ensure traceability, transparency, and compliance with FDA requirements. Listing in such registries is important because it provides stakeholders—including healthcare providers, regulators, and patients—with verified information about the device’s identity, classification, and regulatory status.

Xavant Technology’s devices are classified as either Class I or Class II under regulatory frameworks like the FDA’s classification system. Class I devices generally pose minimal risk and require less stringent regulatory oversight, while Class II devices carry a higher risk and require additional controls to ensure safety and effectiveness. The classification determines the level of scrutiny, labeling requirements, and post-market surveillance needed, ensuring the device meets appropriate standards for its intended use.